Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Navoximod |
Synonyms | |
Therapy Description |
Navoximod (GDC-0919) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases production of kynurenine from tryptophan, potentially resulting in reduced T-cell suppression and increased antitumor immune response (PMID: 31124055, PMID: 29247038). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Navoximod | NLG919|RG6078|GDC-0919|RO7077339-001 | IDO1 Inhibitor 12 | Navoximod (GDC-0919) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases production of kynurenine from tryptophan, potentially resulting in reduced T-cell suppression and increased antitumor immune response (PMID: 31124055, PMID: 29247038). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02048709 | Phase I | Navoximod | IDO Inhibitor in Advanced Solid Tumors | Completed | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |